MedPath

Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes

Conditions
Obesity
Type 2 Diabetes Mellitus
Interventions
Procedure: Bariatric surgery involving Roux-en-Y gastric bypass
Procedure: Bariatric surgery involving Laparoscopic adjustable gastric banding
Procedure: Bariatric surgery involving Laparoscopic sleeve gastrectomy
Registration Number
NCT02328599
Lead Sponsor
Ali Aminian
Brief Summary

Initially, 4 teams of investigators conducted randomized controlled trials (RCT) at their own site to evaluate the effectiveness of bariatric surgery compared to medical/lifestyle management of type 2 diabetes. Each study followed subjects for a duration of about 1 - 3 years. Following this, a consortium was created to pool data and continue to follow study participants. This early collaboration of the 4 groups of investigators was supported by Industry sponsors (Ethicon, Inc and Medtronic-MITG). Now, the investigators have successfully received a grant from the NIH, as the sole supporter of continued observational follow-up of study participants.

The continuing aim of this study is to combine data from the 4 studies and follow the original randomized subjects for an additional 5 years of follow-up. The purpose of the study is to determine the longer term durability and effectiveness of bariatric surgery compared to medical/lifestyle intervention on the treatment of type 2 diabetes.

Detailed Description

The four investigative groups initiated their individual RCT's at their respective sites to evaluate the effectiveness of bariatric surgery compared to multidisciplinary medical and lifestyle management of diabetes and body weight. The original trials were each designed to assess feasibility over a relatively short duration of follow-up (1-3 years). Individually, each trial lacked the sample size and duration of follow-up to meaningfully inform clinical decision making. Together, with the funding provided by the NIH for longer follow-up, the Consortium trial can provide a unique national resource to address timely and unanswered clinical questions related to the durability of these alternative management approaches in patients with T2D and obesity. Together, participants from these studies represent the largest cohort with diabetes (one third having a BMI \<35 kg/m2) ever to undergo randomized assignment to bariatric surgical procedure vs. medical/lifestyle intervention.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
302
Inclusion Criteria
  • Original inclusion criteria for participation in the RCTs at all sites included:

    • Candidate for general anesthesia or unsupervised exercise.
    • Age ≥20 and ≤65 years.
    • Body mass index >27 and ≤45 kg/m2.
    • Diagnosis of type 2 diabetes confirmed by either requiring diabetes medication and/or having elevated glycemia based on HbA1c, fasting plasma glucose, and/or oral glucose tolerance test (OGTT) results, according to American Diabetes Association criteria.
    • Ability and willingness to participate in the study and agree to any of the research arms.
    • Able to understand the options and to comply with the requirements of each program.
    • Negative urine pregnancy test at screening and baseline visits (prior to surgery) for women of childbearing potential (i.e., biologically capable of becoming pregnant).
Exclusion Criteria
  • Subjects who were randomized in one of the four RCTs but never initiated intervention / did not receive randomized treatment
  • Refusal to sign informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
SurgicalBariatric surgery involving Laparoscopic adjustable gastric bandingPrior Bariatric surgery
SurgicalBariatric surgery involving Roux-en-Y gastric bypassPrior Bariatric surgery
SurgicalBariatric surgery involving Laparoscopic sleeve gastrectomyPrior Bariatric surgery
Primary Outcome Measures
NameTimeMethod
Change in HbA1c7 years and up to 13 years for earliest enrollees

Between group (medical vs. surgical) in HbA1c from baseline to 7 year for all participants and up to 13 years for the earliest enrollees

Secondary Outcome Measures
NameTimeMethod
HbA1c < 6.5%7 years and each annual visit through the last known follow-up for all patients up to 13 years

percent of those achieving diabetes remission without the need for anti-diabetic medications

Trial Locations

Locations (4)

University of Pittsburg Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Cleveland Clinic Digestive Disease Institute

🇺🇸

Cleveland, Ohio, United States

University of Washington

🇺🇸

Seattle, Washington, United States

Joslin Diabetes Center

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath